The Bristol-Myers Squibb and Pfizer pharmaceutical companies are facing allegations of a potential class action lawsuit relating to the use of Eliquis, an anticoagulant. The lawsuit claims that Eliquis caused internal bleeding and partial blindness, and the drug manufacturers failed to adequately warn of these risks. The anticoagulant was marketed as a treatment for blood clots to prevent heart attacks.
Allegations
In the Eliquis bleeding risk lawsuit, a California resident alleges that the drug maker failed to adequately warn consumers about the risks of uncontrollable bleeding caused by the use of the blood thinner. The man was taking Eliquis for irregular heartbeats when he experienced fatal bleeding from the gastrointestinal tract. The woman claims that Bayer failed to adequately warn about the risks of uncontrollable bleeding and its severe consequences, including reduced quality of life and decreased lifespan.
In this lawsuit, the drug manufacturers failed to disclose the bleeding risks associated with the drug, and a third party who used the product filed a separate case. The Eliquis lawsuits are centered on the ARISTOTLE study’s fraudulent misrepresentation of data. Both Pfizer and Bristol-Myers deny these claims, and the companies are defending their products.
Class action
There have been numerous reports of people who have suffered from severe bleeding while taking the blood thinner Eliquis. These lawsuits allege that the drug’s manufacturers failed to adequately warn patients about the bleeding risk. The lawsuits seek financial compensation for medical bills, lost wages, and mental anguish. In some cases, lawsuit compensation could even cover physical pain and loss of quality of life. But how does an Eliquis bleeding risk class action lawsuit work?
Thousands of lawsuits against Eliquis were settled for a total of $650 million. The settlements cover up to $150,000 in medical bills, lost wages, pain, and suffering, and other costs. While the law cannot restore lost health or reverse medical errors, it can make sure the party responsible pay for their mistakes. Eliquis patients may even be eligible to recover the cost of emergency room visits, ongoing medical care, and missed work time.
Reversal agent
A new lawsuit alleges that Portola Pharmaceuticals and Eliquis failed to warn patients and doctors about the potential risk of uncontrollable bleeding caused by the blood-thinning drug. The lawsuit focuses on the use of Eliquis, part of a new class of anticoagulants. In the lawsuit, a Louisiana man suffered internal eye bleeding and eventual partial blindness. He claims that the company failed to tell him about the risk of bleeding when he has prescribed the drug.
The Eliquis bleeding side-effect lawsuit claims that the drug manufacturer failed to provide an effective reversal agent for the medication. Without a reversal agent, patients may experience severe internal bleeding. The absence of a reversal agent means that the drug has no way to stop the bleeding if it begins. This is a serious problem for patients who take this medication.
FDA warnings
In a recently FDA-approved drug safety communication, ELIQUIS was warned about the risk of prolonged bleeding. The drug is also associated with an increased risk of bruising and hypovolemia. According to the FDA warnings, patients should stop taking ELIQUIS if they are about to undergo elective surgery or any invasive procedure. Moreover, patients should let their doctors know about any unusual bleeding before undergoing any dental procedure, surgery, or new drug.
Despite the risks associated with anticoagulants, women taking ELIQUIS for a prolonged period are at risk of uncontrolled bleeding. The medication has no known reversal agent for uncontrolled bleeding. The FDA is aware of the risks but hasn’t done enough to reduce the occurrence of bleeding. Therefore, the company has been ordered to increase the labeling of its medication to alert consumers of this risk.
Adequate testing
There are currently several lawsuits pending against Eliquis for inadequate testing of its effects on the human body. A class action lawsuit filed by Eliquis patients claiming injuries is currently being investigated by Saiontz & Kirk, P.A. The Pradaxa drug was introduced in October 2010, but it was soon linked to severe bleeding problems and wrongful death. The plaintiffs in this lawsuit claim that Eliquis did not adequately test for bleeding risks, even though the drug’s manufacturer had warned physicians about the potential for serious bleeding problems.
The lawsuit aims to recover damages for the Texas man who suffered from severe cerebral bleeding while taking Eliquis. The Texas man has filed a lawsuit against Bristol-Myers Squibb, Pfizer, and the Delaware Superior Court, alleging that the drug makers failed to adequately test for the drug’s risk of bleeding. Among other things, the lawsuit says that the manufacturers knew or should have known about the potential risk of cerebral hemorrhage but failed to warn of it.